MEDICATION FOR PREVENTION AND CORRECTION OF DIABETES MANIFESTATIONS Russian patent published in 2015 - IPC A61K38/05 A61K31/401 A61P3/10 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of pharmacology and deals with preparation for prevention and treatment of diabetes. Claimed is application of N-phenylacetyl-L-prolylglycine ethyl ether and created on its base nootropic and neuroprotective medication Noopept as medication for prevention and treatment of diabetes. N-phenylacetyl-L-prolylglycine ethyl ether and Noopept in dose 0,5 mg/kg in combined preventive-therapeutic, preventive and therapeutic, including regimen of delayed therapeutic administration attenuates expression of all metabolic manifestations of diabetes, namely demonstrates antihyperglycaemic effect, recovers normal glucose tolerance under stress conditions, prevents loss of body weight, reduces development of diabetic neuropathy. Noopept surpasses other perorally active standard antidiabetic medication Janow (Sitaglipin) by indices of tolerance to glucose load.

EFFECT: totality of obtained results in combination with numerous clinical data about good tolerance of -phenylacetyl-L-prolylglycine ethyl ether and Noopept makes it possible to consider expedient to apply it by novel indication - as medication of pathogenetic therapy of diabetes, activity of which is aimed at prevention of its progress.

2 cl, 3 dwg, 6 tbl, 5 ex